Valera Vladimir A, Walter Beatriz A, Yokoyama Naoyuki, Koyama Yu, Iiai Tsuneo, Okamoto Haruhiko, Hatakeyama Katsuyoshi
First Department of Surgery, Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi Dori, Niigata City, 951-8510, Japan.
Ann Surg Oncol. 2007 Jan;14(1):34-40. doi: 10.1245/s10434-006-9145-2. Epub 2006 Oct 7.
In this study, an alternative analytical method was used to model colorectal cancer (CRC) patients' long-term survival by assessing the prognostic value of the Ki-67 protein as a marker of tumor cell proliferation, and to illustrate the interaction between standard clinicopathologic variables and the proliferation marker in relation to their impact on survival.
A cohort of 106 surgically treated CRC patients was used for analysis. The expression of the cell-cycle-related Ki-67 protein in tumor samples was evaluated by immunohistochemistry. A score was assigned as the percentage of positive tumor cell staining, denoted as proliferation index (PI), and was used in a multivariate analysis using a recursive partitioning algorithm referred to as classification and regression tree (CART) to characterize the long-term survival after surgery.
Of the covariates selected for their prognostic value, PI contributed most to the classification of survival status of patients. However, CART analysis selected the presence of distant metastasis as the best first split-up factor for predicting 5-year survival. CART then selected the following covariates for building up subgroups at risk for death: (1) PI; (2) pathological lymph node metastasis; (3) tumor size. Seven terminal subgroups were formed, with an overall misclassification rate of 16%.
These analyses demonstrated that a Ki-67-protein-based tumor proliferation index appeared as an independent prognostic variable that was consistently applied by the CART algorithm to classify patients into groups with similar clinical features and survival.
在本研究中,采用了一种替代分析方法,通过评估Ki-67蛋白作为肿瘤细胞增殖标志物的预后价值,对结直肠癌(CRC)患者的长期生存进行建模,并阐明标准临床病理变量与增殖标志物之间的相互作用及其对生存的影响。
选取106例接受手术治疗的CRC患者作为分析队列。通过免疫组织化学评估肿瘤样本中细胞周期相关Ki-67蛋白的表达。将阳性肿瘤细胞染色百分比作为一个评分,记为增殖指数(PI),并在多变量分析中使用一种称为分类回归树(CART)的递归划分算法,以描述术后的长期生存情况。
在因其预后价值而选择的协变量中,PI对患者生存状态的分类贡献最大。然而,CART分析选择远处转移的存在作为预测5年生存率的最佳首要划分因素。CART随后选择以下协变量来构建死亡风险亚组:(1)PI;(2)病理淋巴结转移;(3)肿瘤大小。形成了7个终末亚组,总体错误分类率为16%。
这些分析表明,基于Ki-67蛋白的肿瘤增殖指数是一个独立的预后变量,CART算法持续应用该指数将患者分为具有相似临床特征和生存情况的组。